Dicerna appoints Patrick Gray to Board of Directors

Dicerna has announced Retirement of Board of Director Veteran Dennis Langer, and to his place has named Patrick Gray.

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Patrick Gray to the Dicerna board of directors (the “board”) as an independent director, and the retirement of veteran director Dennis Langer, M.D., J.D. Mr. Gray will serve as the chairperson of the Audit Committee. Mr. Gray’s appointment is effective immediately.

“As Dicerna continues to grow and mature, our board continues to evolve with the addition of Patrick Gray. Patrick is an accomplished CPA, executive, and director who brings with him extensive industry experience that will help further advance our GalXC-based pipeline and strengthen Dicerna’s position in the promising field of RNAi therapeutics,” said Douglas M. Fambrough, Ph.D., president and chief executive officer of Dicerna. “We sincerely thank Dennis Langer, who has been on our board since 2007, for his meaningful and numerous contributions over the years. Dennis has played a key role in the growth of our company with his strategic insights, sage counsel, and guidance.”

Mr. Gray currently serves as a member of the board and as chairperson of the audit committee of Tmunity Therapeutics, Inc. He previously served as a member of the board and as the chairperson of the audit committee of Civitas Solutions, Inc., from September 2014 to March 2019, Sancilio Pharmaceuticals Company, Inc., from February 2012 through August 2018, and Datto, Inc., from May 2015 through December 2017. Mr. Gray spent 37 years with PricewaterhouseCoopers LLP (“PwC”) until his retirement in 2009. He is a certified public accountant who spent 25 years as an Audit Partner at PwC. At the time of his retirement, he served as the lead partner for the PwC U.S. firm’s Corporate Governance Group. Prior to that time, Mr. Gray held various other leadership positions within the firm, including leadership of the PwC U.S. High Technology Group. Mr. Gray holds a B.S. in Economics from The Wharton School, University of Pennsylvania.

“I am pleased to join the Dicerna board of directors at such an important time for the company as it advances its promising pipeline and engages in strategic partnerships with leading pharmaceutical companies to further extend the potential of its technology,” commented Mr. Gray. “I look forward to helping Dicerna continue to execute on and achieve its goal of developing and delivering innovative and effective therapies for patients in need.”